These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21540324)

  • 21. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
    Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
    World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    Unger JM; Till C; Thompson IM; Tangen CM; Goodman PJ; Wright JD; Barlow WE; Ramsey SD; Minasian LM; Hershman DL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27565902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
    Ornstein DK; Rao GS; Smith DS; Andriole GL
    J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up.
    Lam JS; Romas NA; Lowe FC
    Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Kratz M; Thompson IM
    Am J Epidemiol; 2010 Mar; 171(5):571-82. PubMed ID: 20142396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea.
    Lee JY; Lee SH; Kim SJ; Kim CS; Lee HM; Kim CI; Chung BH
    Urology; 2011 Jan; 77(1):171-6. PubMed ID: 20691464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
    Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
    Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Kristal AR; Till C; Platz EA; Song X; King IB; Neuhouser ML; Ambrosone CB; Thompson IM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):638-46. PubMed ID: 21335507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Sutcliffe S; Grubb Iii RL; Platz EA; Ragard LR; Riley TL; Kazin SS; Hayes RB; Hsing AW; Andriole GL;
    BJU Int; 2012 Oct; 110(7):1050-9. PubMed ID: 22429766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.
    Brasky TM; Till C; White E; Neuhouser ML; Song X; Goodman P; Thompson IM; King IB; Albanes D; Kristal AR
    Am J Epidemiol; 2011 Jun; 173(12):1429-39. PubMed ID: 21518693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
    Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
    BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.